OBJECTIVE:
The prevalence of postpartum anemia varies from 4 -27%. This study aims to compare the tolerability and efficacy of intravenous (IV) iron sucrose and oral ferrous bis-glycinate (fbg) in treatment of postpartum iron deficiency anemia (IDA). STUDY DESIGN: An open labeled randomized clinical trial was carried out in a tertiary University hospital between December 2016 and March 2018. The study included women who were delivered either vaginally or by cesarean section proved to have a postpartum IDA (hemoglobin < 11 g/dL). Participants were randomized in a 1:1 ratio to the two study groups: Group I: IV iron sucrose group received IV iron sucrose (sacrofer ampules 100 mg/5ml, Amoun Pharmaceutical Company, Egypt) A patient's total body iron deficit were calculated using the Ganzoni formula (total iron dose ¼ [body weight (kg) Â (15-actual Hb)] Â 2.4 + 500 mg) then the total dose was divided on 3 settings. Group II: Oral ferrous bis-glycinate group received oral FBG fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets, DEVART LAB under the license of NOVOTECH, USA) once daily for 42 days. The primary study outcome was the mean rise in Hb level after 6 weeks treatment. RESULTS: The study included 150 women in the final analysis. No difference between both groups regarding the baseline characteristics. The mean increase in HB level after 6 weeks of treatment in IV iron sucrose group was 2.75AE 0.33 g/dL versus 2.45AE0.38 g/dL in FBG group (p¼ 0.001). The percentage of women with Hb level >11 g/dL after 6 weeks of treatment was 89.2% in IV iron sucrose group versus 71.3% in FBG group (p <0.001). The rate of adverse effects was significantly higher in FBG group (p¼ .001) especially nausea and constipation. CONCLUSION: Women with postpartum IDA is better treated with IV iron sucrose which is more efficient in increasing Hb level. Moreover, it has tolerable adverse effects and high compliance than oral FBG. 
The current study aims to evaluate the accuracy of an ultrasonographic placenta accreta index (PAI) for diagnosing morbidly adherent placenta (MAP). STUDY DESIGN: This study was a prospective cohort study included pregnant women referred to our ultrasound unit in a tertiary university hospital from March 2016 to February 2018 because of suspected MAP on a previous ultrasound examination All women were assessed using the PAI score based on the following: number and size of placental lacunae; presence of bridging vessels; the sagittal smallest myometrial thickness, the uterine-bladder interface thickness and the placental location. Additionally, the number of previous Cesarean deliveries was determined. All ultrasonographic evaluations were performed by an expert level II sonographer.
The presence of MAP was determined by the surgeon at delivery and clinical data were recorded at time of delivery. Pathological diagnoses of placental invasion were available only in patients that underwent hysterectomy. RESULTS: In total, 137 pregnant women were included in the study, of whom 33 (24.1%) were diagnosed with MAP. The mean PAI score in women with focal accreta was significantly higher than the PAI score of placenta previa non-accreta (6.50AE1.81 vs. 3.63AE1.98, p<0.001). Similarly, the mean PAI score in women with total accrete was significantly higher than non-accreta (8.71AE0.28 vs. 3.63AE1.98, p<0.001). Receivereoperating characteristics (ROC) curve for prediction of MAP using PAI score yielded an area under the ROC curve of 0.911. The best cut-off point was 5.25 with 86% sensitivity and 88% specificity. All sonographic criteria of the PAI were significantly associated with MAP (p<0.0001). ROC curves for prediction of MAP using the number of placental lacunae and smallest myometrial thickness yielded an area under the ROC curve of 0.856 and 0.783 respectively. CONCLUSION: PAI is highly predictive of morbidly adherent placenta in patients at risk. This allows an adequate pre-operative planning and accurate timing of delivery in such cases Poster Session IV Chi-square and Student's T-test statistical analysis was performed, and receiver-operator characteristic curves were plotted for the prediction of each category of perinatal outcome and the areas under the curves were determined. All p-values were two-sided, and P <0.05 was considered statistically significant. RESULTS: Examination of the pregnancy outcomes and clinical features of the 61 patients diagnosed with ICP showed no occurrence of IUFD, stillbirth, abruption, or neonatal demise. In our cohort, no single factor was identified that correlated with a reassuring outcome and would permit expectant management of pregnancy beyond 37 weeks gestation.
ROC curve analysis revealed a statistically significant correlation between bile acid and AST levels and perinatal outcomes. A bile acid level equal to or greater than 37 mmol/L strongly predicted spontaneous preterm labor in women affected by ICP with a sensitivity of 100% and specificity of 60.70% (P value 0.002). A bile acid level equal to or greater than 42 mmol/L strongly predicted meconiumstained amniotic fluid with a sensitivity of 85.70% and specificity of 66.70% (P value 0.006). AST levels equal to or greater than 62 IU/L strongly predicted NICU admission with a sensitivity of 81.30% and specificity of 62.20% (P value 0.002). AST levels equal to or greater than 75 IU/L strongly predicted hyperbilirubinemia in the neonates with a sensitivity of 87.50% and specificity of 69.80% (P value 0.001).
CONCLUSION:
There is a statistically significant correlation between elevated bile acid and AST levels and adverse perinatal outcomes. Given this statistically significant correlation, patients with ICP should undergo serial liver function tests, specifically AST levels, along with serial bile acid levels.
Although we had positive correlations between adverse perinatal outcomes and bile acid level and aspartate-aminotransferase levels, we investigated short-term outcomes, and whether long-term sequellae exist has yet to be elucidated. As per our data analysis, a subcategory of patients with ICP and abnormal LFTs also need to be separately studied.
818 Correlation of self-reported depressed mood using telehealth and 6-week EPDS in postpartum women with hypertension This was a secondary analysis of a TH program for a postpartum hypertension: non-randomized control trial. TH patients were asked twice weekly for 6 weeks if their mood "has been more depressed this week compared to a normal week," along with taking routine vitals. The controls received routine care after discharge, which included an EPDS questionnaire at the 6-week postpartum visit. EPDS scores were collected from the EMR at the visit for all study participants. RESULTS: 214 TH participants and 214 concurrent controls were included in this analysis. Maternal demographics were similar between groups, though TH participants had more severe HTN disorders and were more likely to have undergone CD. Among both groups, the rate of a previous mental health diagnoses was similar at 32%. During postpartum week 1, 29 (16%) participants reported a more depressed mood based on the TH screening question. These rates decreased weekly, with only 3 (5%) participants reporting depressed mood by week 6. This did not correlate well with the 6-week EPDS in which 22 (12.7%) of TH patients screened positive.
